Physician profile
Catherine He
NPI 1912536160
$2,304.95
in general payments reported to CMS, 2019-2025
15 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $98.33 · 2024: $556 · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Travel and Lodging: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.18 |
| Travel and Lodging | $822.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $950.96 | 2025 | |
| Sun Pharmaceutical Industries INC. | $241.27 | 2024-2025 | |
| Abbvie INC. | $174.25 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $165.46 | 2024-2025 | Acthar |
| Amgen INC. | $147.24 | 2025 | Tepezza |
| Harrow Eye, LLC | $128.45 | 2024-2025 | Vevye |
| Ani Pharmaceuticals, INC. | $101.93 | 2025 | Purified Cortrophin Gel, Iluvien |
| Oyster Point Pharma, INC. | $82.94 | 2024-2025 | Tyrvaya |
| Astellas Pharma US INC | $46.32 | 2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $44.94 | 2025 | Xdemvy |
| Dompe US, INC. | $34.11 | 2025 | Oxervate |
| Alcon Vision LLC | $24.41 | 2025 | Simbrinza |
| Genentech USA, INC. | $23.54 | 2025 | Vabysmo |
| Thea Pharma INC. | $21.82 | 2025 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $18.98 | 2024 | Rayone Emv, Rayone Spheric, Rayner Cataract Set 1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.